Teresa DeLuca, MD, MBA, was named in the “2022 Director of the Month” by the Chief Executive Group and was also named “2020 Director to Watch” in the Directors & Board Annual Report. She is a physician executive (with an active medical licenses) and a former CMO/SVP and business unit P&L owner with 20+ years of experience running large divisions at Fortune 50+ healthcare companies.
She is presently serving as an Independent Public Board Member and as the Founding Chair of Compliance & Ethics Committee and member of the Audit Committee for Surgery Partners [NASDAQ:SGRY]. She also serves on Life Stance {NASDAQ:LFST] board and serves as Chair of the Compliance & Quality Committee. Teresa is the Chair of Remuneration Committee and Chair of Nomination Committee for Rejuveron a private Swiss platform drug discovery company. Previously she served as Independent Public Board Member and was the Chair of Compensation Committee and on the Nominating & Governance for 180 Life Sciences [NASDAQ:ATNF]. She also previously served as Board Member of North Bud (CSX: NBUD) when it was a private company and continued to serve through the IPO and for two terms on the public company as an Independent Director on the Audit Committee and Chair the Governance Committee.
Previously Teresa was the Managing Director of Columbia University’s NY Life Science Venture, a consortium including eleven other NYC public and private medical and research institutions. Teresa has been the Chief Medical Officer for Magellan, SVP at Humana, National Medical Director & VP for Clinical Sales at Walgreen Co. and CMO/VP, Personalized Medicine, Clinical Quality & Medical Policy at Medco. Prior to taking on these senior executive leadership roles, Teresa was Senior Director of Global Product Development Services at PRA International and Senior Medical Scientist at GlaxoSmithKline.
Noted for trendsetting repositioning, she oversees strategic acquisitions and divestitures, leads P&L divisions, operations, clinical management and sales within all healthcare verticals. Her work was honored with Fortune’s Most Innovative Company award, People Choice Stevie award, and Fast Company’s Innovation List award.
Teresa created a first-to-market personalized medicine business that increased earnings per share resulting in a stock split within its first year. She handled P&L of $1.3 billion and guided a staff of 900+ employees over six time zones for the nation’s 4th largest healthcare company, and was brought in by the CEO to lead the $525 million divestiture.
Breaking into new markets, formulating business plans and strategy are all “hats” she have worn. She was Co-Founder & Co-Owner of a luxury consumer goods company that within the first year received reviews and awards published or presented by The New York Times, Oprah Magazine, Wall Street Journal, Vogue, New York Magazine and Access Hollywood. And after 18 months sold the business for a 150% return on capital.
A sought-after speaker who delivers presentations at symposia and conferences throughout the U.S. and internationally, Teresa is also quoted in national news publications and interviewed live on multiple network television and news shows.
Teresa is a (NACD) National Association of Corporate Directors Board Leadership Fellow, Master Level as well as a NACD Board Advisory Faculty Member. She is considered a NACD “Subject Matter Expert” and serves as a Certification Commissioner. In addition, she passed the NACD’s “Directorship Certified” [NACD.DC] examination, earned the Carnegie Mellon Cybersecurity Certificate and passed the Digital Directors Network Cyber Risk Masterclass for Public Companies. Teresa also earned the American College of Corporate Directors (ACCD) “Master Professional Director – Public Company” credential.
Dr. DeLuca maintains a current New York State Medical License, a DEA License and is both Buprenorphine Certified and a NYS Medical Marijuana Prescriber. She was Chief Psychiatric Resident at Jefferson Medical College in Philadelphia and an Assistant Clinical Professor of Psychiatry at Mount Sinai Medical School in New York. She has served on the editorial board of “American Health & Drug Benefit Journal”, writes commentary in peer reviewed professional and industry journals. She is a Faculty Advisor at Columbia University School of Entrepreneurship and Faculty Member of Columbia University School of Professional Studies.
Teresa is an elected Co-Chair and Leadership Council Member for the international organization, Women Corporate Directors (WCD) as well as a member of both the Committee of 200 (C200) and Women Business Collaborative (WBC). She has served as a Director on the Boards of Visions Services for the Blind, ChopChop and Spoons Across America, as well as the Advisory Boards of the American Red Cross (Greater NY Chapter), Springboard Life Science Council, Women Business Leaders (WBL), the Healthcare Business Association (HBA) and the James Beard Foundation (JBF).
